Are you wondering if the 5-10 year survival data for mantle cell lymphoma (MCL) is outdated, and whether people are living longer than expected?
The good news is that survival rates for MCL are improving over time. While older studies showed median overall survival of 6-10 years, people diagnosed after 2000 have shown a Show Full Answer
Are you wondering if the 5-10 year survival data for mantle cell lymphoma (MCL) is outdated, and whether people are living longer than expected?
The good news is that survival rates for MCL are improving over time. While older studies showed median overall survival of 6-10 years, people diagnosed after 2000 have shown a median overall survival of 11.25 years. This means half of people with MCL are living beyond that timeframe.
New treatments have made a significant difference. The development of therapies like rituximab and bone marrow transplants means people with MCL today have a better prognosis compared to 20 years ago. The five-year overall survival rate for advanced-stage MCL is around 65 percent, and this continues to improve as newer treatments become available.
It's worth noting that much of the published data comes from studies conducted several years ago, so current outcomes may be even better than what the statistics show. Clinical trials are also exploring newer, more effective treatments that could further improve long-term outcomes.
Your individual prognosis depends on several factors including your age, disease stage, performance status, and specific characteristics of your lymphoma cells. Staying in close communication with your oncologist about newer treatment options and maintaining your treatment plan can help optimize your outcomes.
March 29
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
